CTOs on the Move

Tanabe Research Laboratories U.S.A.

www.trlusa.com

 
Tanabe Research Laboratories U.S.A., Inc. (TRL), is a wholly owned subsidiary of Tanabe Seiyaku Co., Ltd., headquartered in Osaka, Japan. The Research staff of TRL are highly skilled in biology and/or chemistry and at working in a collaborative
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.trlusa.com
  • 4540 Towne Centre Ct
    San Diego, CA USA 92121
  • Phone: 858.622.7000

Executives

Name Title Contact Details

Similar Companies

VoCare

The Vitals 360® measures 6 key vital signs. It´s like having a portable doctor´s office in the home or anywhere. Heart Rate Blood Pressure Blood Oxygen Saturation ECG Heart Rhythms Temperature Glucose (Not available in the...

OmegaChem

OmegaChem is a Levis, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Red Nucleus

Red Nucleus is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OrthoArizona

Enjoy the freedom of a pain-free, active lifestyle with help from our orthopedic specialists at OrthoArizona. Learn more today!

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.